InnovAtlasMalaria No More
Research institution

Columbia University Irving Medical Center — Fidock Lab / Center for Malaria Therapeutics and Antimicrobial Resistance; Department of Microbiology & Immunology; Department of Medicine (Division of Infectious Diseases)

DiscoverDevelop

The Fidock laboratory develops antimalarial drug targets and studies how malaria parasites become resistant to medicines, using genetics, molecular biology, and pharmacology-based approaches.

2
Endemic countries
1
U.S. states
4
Products and programs
About

What they do

The Fidock laboratory develops antimalarial drug targets and studies how malaria parasites become resistant to medicines, using genetics, molecular biology, and pharmacology-based approaches.1,2,3 Its U.S. R&D is based at Columbia University Irving Medical Center in New York City.2,3 The work spans the discovery and development stages, from target and mode-of-action studies through resistance-risk assessment and marker development for antimalarials in development.2,1,3

In the United States
Products and programs

In the field and in development

Center for Malaria Therapeutics and Antimicrobial Resistance1,3
Malaria Drug Accelerator (MalDA) drug-target discovery4,3
PfCRT/PfMDR1/Kelch13 drug-resistance program3
PfCRT structure-guided resistance prediction and validation3
Where they work

Partnerships in 2 endemic countries

Surveillance and genomicsResearch
Ethiopia
Africa
  • Addis Ababa University · molecular surveillance and characterization of artemisinin resistance in Plasmodium falciparum, in collaboration with Université de Strasbourg/Institut Pasteur5,3
  • University of Cape Town · MalDA drug-discovery consortium collaborator4,3
U.S. partners

Who they work with in the United States

Sources

Where this comes from

  1. 1infectiousdiseases.cuimc.columbia.edu
  2. 2infectiousdiseases.cuimc.columbia.edu
  3. 3Confirmed by the organization
  4. 4malariada.org
  5. 5cuimc.columbia.edu